Serum C-X-C motif chemokine ligand 9, interleukin 8, and interleukin 22 as key biomarkers in pediatric inflammatory bowel disease

Table 2 Demographic and disease characteristics, n (%)

	All (n = 246)	IBD (n = 155)	Non-IBD (n = 91)
Age at diagnosis median (IQR; year)	11.63 (8.56-13.95)	11.15 (9.17-15.08)	11.68 (8.48-13.83)
Female	44 (34.37)	10 (35.71)	34 (34)
Crohn's disease	103 (41.9)	103 (66.4)	0
UC	46 (18.7)	46 (29.7)	0
IBD-U	6 (2.4)	6 (3.9)	0
Ethnicity
Western European	175 (71.1)	106 (68.4)	69 (75.8)
South Asian	32 (13)	22 (14.2)	10 (10.9)
Other	39 (15.8)	27(17.4)	12 (13.2)
Biologic treatment at 1 year		48 (39)
Activity score at diagnosis
Remission		4 (2.58)
Mild		96 (61.93)
Moderate-severe		50 (32.25)
Missing		5 (3.2)
Crohn's disease (n = 103)
Behavior
B1		93 (90.3)
B2		6 (5.8)
B3		4 (3.9)
Location
L1		17 (16.7)
L2		30 (39.4)
L3		55 (53.4)
L4		50 (48.5)
Perianal disease		34 (33)
UC/IBD-U (n = 52)
Location
E1		13 (25)
E2		12 (23.1)
E3		10 (19.2)
E4		17 (32.7)
Diagnosis
IBS/functional abdominal pain			38 (41.8)
Infection			6 (6.6)
Other inflammatory disease			16 (17.6)
Polyp			12 (13.2)
Other			19 (20.9)

Remission: Pediatric ulcerative colitis activity index (PUCAI)[29]/pediatric Crohn's disease activity index (PCDAI)[30] < 10; Mild: PUCAI 10-34, PCDAI 10-30; Moderate-severe: PCDAI > 30, PUCAI > 35. IBD-U: Inflammatory bowel disease unspecified; IBS: Irritable bowel syndrome; IQR: Interquartile range; PCDAI: Pediatric Crohn's disease activity index; PUCAI: Pediatric ulcerative colitis activity index; UC: Ulcerative colitis.